IN2014MN02562A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02562A IN2014MN02562A IN2562MUN2014A IN2014MN02562A IN 2014MN02562 A IN2014MN02562 A IN 2014MN02562A IN 2562MUN2014 A IN2562MUN2014 A IN 2562MUN2014A IN 2014MN02562 A IN2014MN02562 A IN 2014MN02562A
- Authority
- IN
- India
- Prior art keywords
- alkyl
- con
- heterocyclyl
- further described
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
The invention relates to a compound of the general formula (I) or a physiologically functional derivative solvate or salt thereof (I) wherein A is a bond alkyl or alkoxy optionally substituted with one or more R' as defined herein * N(R' )CO * CON(R' ) * N(R ')CON(R' ) S SO * N(R ') * N(R ')CO * CON(R ') CO * COO * OOC * S0N(R' ) S0 or * N(R' ) SO wherein R' is as defined herein and * specifies the point of attachment to X; X is aryl cycloalkyl aralkyl heterocyclyl or heteroaryl which may be substituted with one or more R further described herein; L is a bond or * N(R)CO * CON(R) * N(R) * C=N(R) * N(R) alkyI * alkyl N(R) * N(R)CON(R) * CO * S0 alkyl * alkyl 0 alkyl * NCO CH=CH * CH=CH CONH * S0N(R) * N(R)S0 or heterocyclyl wherein * specifies the point of attachment to X; Y is H alkyl aryl aralkyl cycloalkyl heterocyclyl or heteroaryl which may be substituted with one or more R further described herein; and R and R are further described herein; as well as their use as a medicament a pharmaceutical composition comprising them a method of treatment or prevention of a medical condition entailing the administration thereof and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition particularly autoimmune inflammatory disorders CNS disorders sleeping disorders or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02562A true IN2014MN02562A (en) | 2015-07-24 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2562MUN2014 IN2014MN02562A (en) | 2012-06-27 | 2013-06-27 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (en) |
| EP (1) | EP2867237A1 (en) |
| JP (2) | JP6272846B2 (en) |
| KR (1) | KR102155559B1 (en) |
| CN (1) | CN104540831B (en) |
| AU (2) | AU2013283318B2 (en) |
| BR (1) | BR112014032581A8 (en) |
| CA (1) | CA2877589C (en) |
| EA (1) | EA029718B1 (en) |
| HK (1) | HK1204474A1 (en) |
| IL (1) | IL236463A0 (en) |
| IN (1) | IN2014MN02562A (en) |
| MX (1) | MX350418B (en) |
| MY (1) | MY167785A (en) |
| NZ (1) | NZ702618A (en) |
| SG (1) | SG11201408617PA (en) |
| UA (1) | UA116541C2 (en) |
| WO (1) | WO2014001464A1 (en) |
| ZA (1) | ZA201409194B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
| CA2943220C (en) | 2014-03-20 | 2024-01-16 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| CN106661027B (en) | 2014-03-20 | 2019-12-24 | 卡佩拉医疗公司 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
| WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| HRP20220936T1 (en) * | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| KR20200090154A (en) | 2017-10-27 | 2020-07-28 | 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 | Composition and method for modulating immune response by activation of alpha protein kinase 1 |
| BR112021003665A2 (en) | 2018-09-13 | 2021-05-18 | Bayer Aktiengesellschaft | heterocyclene derivatives as pest control agents |
| CN109020990A (en) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | Phenyl benzofurans compound, and preparation method thereof, composition and medical usage |
| KR102119150B1 (en) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | A pharmaceutical composition for preventing or treating cancer comprising as an active ingredient N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| JP7327855B2 (en) | 2020-06-26 | 2023-08-16 | ラクオリア創薬株式会社 | METHOD FOR SELECTING CANCER PATIENTS FOR EFFECTIVE RETINOID AND CANCER THERAPEUTIC COMBINATION THERAPY AND COMBINATION MEDICINE OF RETINOID AND CANCER THERAPEUTIC |
| CN116942819A (en) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | Application of microtubule-associated serine/threonine-like kinase inhibitor in preparation of medicines for treating tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| ATE511840T1 (en) | 2001-10-09 | 2011-06-15 | Amgen Inc | IMIDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-substituted-5- and 6-Aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I |
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| EP1957078B1 (en) | 2005-12-02 | 2013-08-28 | Bayer HealthCare, LLC | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20080403A1 (en) * | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
| FR2918061B1 (en) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| SG10201501272SA (en) * | 2009-10-22 | 2015-04-29 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
-
2013
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
- 2013-06-27 UA UAA201500560A patent/UA116541C2/en unknown
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/en not_active Expired - Fee Related
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/en not_active Application Discontinuation
- 2013-06-27 EA EA201500050A patent/EA029718B1/en not_active IP Right Cessation
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 MX MX2014015938A patent/MX350418B/en active IP Right Grant
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/en active IP Right Grant
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/en not_active Expired - Fee Related
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/en unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/en active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1204474A1 (en) | 2015-11-20 |
| AU2018201275A1 (en) | 2018-03-15 |
| MX350418B (en) | 2017-09-06 |
| EA029718B1 (en) | 2018-05-31 |
| CN104540831A (en) | 2015-04-22 |
| JP2015525742A (en) | 2015-09-07 |
| BR112014032581A8 (en) | 2018-08-14 |
| SG11201408617PA (en) | 2015-01-29 |
| KR102155559B1 (en) | 2020-09-15 |
| NZ702618A (en) | 2016-12-23 |
| WO2014001464A1 (en) | 2014-01-03 |
| JP6272846B2 (en) | 2018-01-31 |
| US20150158878A1 (en) | 2015-06-11 |
| EP2867237A1 (en) | 2015-05-06 |
| EA201500050A1 (en) | 2015-09-30 |
| US9580438B2 (en) | 2017-02-28 |
| CN104540831B (en) | 2017-11-07 |
| MY167785A (en) | 2018-09-25 |
| BR112014032581A2 (en) | 2017-06-27 |
| CA2877589A1 (en) | 2014-01-03 |
| MX2014015938A (en) | 2015-07-21 |
| JP2018076360A (en) | 2018-05-17 |
| CA2877589C (en) | 2019-11-26 |
| ZA201409194B (en) | 2017-08-30 |
| IL236463A0 (en) | 2015-02-26 |
| US20170240556A1 (en) | 2017-08-24 |
| AU2013283318B2 (en) | 2017-11-23 |
| KR20150037877A (en) | 2015-04-08 |
| AU2013283318A1 (en) | 2015-01-22 |
| UA116541C2 (en) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02562A (en) | ||
| EP2581376A4 (en) | Matrinic acid/ matrine derivatives and preparation methods and uses thereof | |
| ATE517882T1 (en) | QUINOLINE DERIVATIVES | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| UA109698C2 (en) | AZAINDASOL OR DIAZAINDASOL DERIVATIVES AS A MEDICINE | |
| MX360634B (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof. | |
| EA201070929A1 (en) | FURO-THYENO [3,2-c] Pyridine | |
| IN2014MN00988A (en) | ||
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
| EA201200318A1 (en) | Heterocyclic oximes | |
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| IN2015DN01119A (en) | ||
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| IN2012DN02502A (en) | ||
| WO2011123536A8 (en) | Polycyclic tetracycline compounds | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| HK1190643A1 (en) | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
| IN2013DN02555A (en) | ||
| IN2014DN11023A (en) | ||
| EA201270653A1 (en) | ANTAGONIST DPI ITS APPLICATION | |
| IN2014KN01113A (en) | ||
| IN2015MN00045A (en) |